Drug Database
DI

didanosine (didanosine EC / Videx EC)

✓ Approved

Bristol-Myers Squibb · · 小分子

什么是 didanosine?

didanosine 是一种小分子,由Bristol-Myers Squibb研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名didanosine EC, Videx EC
公司Bristol-Myers Squibb
药物类别小分子
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

didanosine 作用于 1 个分子靶点:

gag-pol, HIV-1 (gag-pol)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

didanosine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsAcquired immunodeficiency syndrome✓ Approved

相关研究文献

PubMedDrugs2026-11-17

Insulin Efsitora Alfa: First Approval.

Blair Hannah A HA

Insulin efsitora alfa (Onswik™) is a once-weekly ultra-long-acting recombinant basal insulin being developed by Eli Lilly and Company for the treatment of diabetes mellitus. Administered once weekly as a subcutaneous injection, insulin efsitora alfa is designed to provide a simplified treatment regimen relative to standard daily basal insulins. On 20 August 2026, insulin efsitora alfa received its first approval in the EU for the treatment of type 2 diabetes mellitus (T2DM) in adults. On 24 September 2026, insulin efsitora alfa was approved in the USA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. Insulin efsitora alfa is approved in the EU, Iceland, Norway, Liechtenstein and the USA and is under regulatory review in the UK and Japan for T2DM. This article summarizes the milestones in the development of insulin efsitora alfa leading to this first approval for T2DM.

PMID 43040187
阅读全文 →
PubMedFrontiers in molecular medicine2026-11-17

Inulin supplementation in well-controlled HIV patients with acquired metabolic disorders is associated with increased zonulin levels- an indirect biomarker of gut permeability.

Vikraman Praveen Kumar PK, Ahmed Shamayl S, Sohail Rubab R, Akerman Meredith M et al.

Human Immunodeficiency Virus (HIV) infection is associated with increased gut permeability resulting in chronic inflammation and elevated levels of zonulin. An optimum diet including fiber has been demonstrated in some cohorts to support a healthy gut microbiome, decrease gut permeability, decrease systemic inflammation, and reduce the risk of developing metabolic disorders. A previous study documented multiple benefits of inulin supplementation in obese/overweight subjects. This pilot study assessed the same soluble fiber supplementation in subjects with-controlled HIV infection and acquired metabolic conditions on zonulin levels and metabolic parameters. Ten participants with well-controlled HIV infection with at least three acquired metabolic disorders were enrolled in the study. Each subject had an initial 1-week lead in period of 12 g orally once daily of the soluble fiber inulin then twice daily for the 42-day study duration. Baseline and post-intervention zonulin levels were analyzed along with various markers of metabolic syndrome. Fiber supplementation was well tolerated. Flatulence and abdominal bloating were experienced by some subjects. There was no significant difference between baseline and post-intervention levels for Body Mass Index (BMI), Hemoglobin A1C (HbA1c), fructosamine or lipid levels. Each subject had an increase in zonulin levels. Median zonulin levels at baseline were 177.9 μg/mL (Interquartile Range [IQR] 97.8-268.6), increasing to post-intervention levels of 532.4 μg/mL (IQR 289.7-1532.70) which was statistically significant (p = 0.002). In contrast to the experience with other patient populations, inulin supplementation was associated with a significant increase in zonulin levels, an indirect biomarker of gut permeability. There were no changes in metabolic parameters. We speculate that underlying pre-existing gut dysbiosis in persons with well-controlled HIV with metabolic disorders may complicate dietary strategies to optimize health. Short term soluble fiber supplementation had no demonstrable benefit in this small sample. Further investigations including direct measures of gut permeability, metabolomics and serial microbiome assessment and additional dietary strategies are needed.

PMID 43041541
阅读全文 →
PubMedThe Medical letter on drugs and therapeutics2026-11-17

Weltruza - a once-monthly subcutaneous formulation of olanzapine.

PMID 43040626
阅读全文 →
PubMedPakistan journal of medical sciences2026-11-17

Association between CYP2D6*10 and ADRB1 Polymorphisms on Metoprolol Efficacy in Hypertensive Patients.

Sun Yu Y, Wang Na N, Yan Xiaojing X

To investigate the association between CYP2D610 and ADRB1 (1165G>C) polymorphisms on metoprolol treatment outcomes in hypertensive patients. A total of 280 hypertensive patients, treated in the First Affiliated Hospital of Qiqihar Medical University between May 2023 to May 2024, who received treatment with metoprolol sustained-release tablets (23.75 mg once daily), were genotyped using Taqman real-time PCR. Patients were divided into nine groups based on CYP2D610 and ADRB1 genotypes. Blood pressure, heart rate, and biochemical markers were monitored to assess metoprolol's efficacy and adverse effects. Metoprolol treatment led to significant reductions in systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate across all genotype groups. The absolute values of SBP change and DBP change were relatively larger in groups seven, eight and nine (CYP2D6*10 homozygous mutant), and the HR decreased in all groups, with no significant differences among genotype groups. The CYP2D6*10 homozygous mutant group (groups seven, eight and nine) had a higher incidence of adverse reactions (15%-25 %) than other groups (2%-5%). No significant differences in alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (Cr), or cystatin C (CysC) levels were observed across genotype groups (P>0.05). This study showed that while metoprolol effectively reduced blood pressure and HR, the extent of the effect was influenced by CYP2D6*10 and ADRB1 (1165G>C) genetic polymorphisms.

PMID 43042230
阅读全文 →
PubMedWound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society2026-11-17

Controlled Cold Stress Modulates Molecular Responses During Cutaneous Wound Healing: A Preclinical Study.

Kim Dong Gyu DG, Park Eun Soo ES

Mild, non-destructive cooling may alter the wound microenvironment without producing cryogenic tissue injury, but its effects on cutaneous wound repair remain uncertain. This study evaluated whether the timing and temperature of controlled superficial cooling were associated with changes in wound closure and molecular responses in a splinted rat excisional wound model. Sixteen Sprague-Dawley rats received three dorsal wounds assigned to untreated control, 3°C cooling, or -3°C cooling. Cooling was initiated either immediately after wounding or on Day 3 and was applied for 10 s once daily for three sessions. Wound healing ratio was assessed on Days 2, 4, and 7 in the Day 7 tissue-harvest cohort and on Day 14 in a separate cohort. Expression of interleukin-1β, interleukin-6, tumour necrosis factor-α, and cluster of differentiation 34 was evaluated on Days 7 and 14. No statistically significant differences in wound healing ratio were detected according to treatment timing or cooling temperature. Molecular expression values were available as averages of two animals and were therefore evaluated descriptively. On Day 7, tumour necrosis factor-α expression was lower and interleukin-6 expression was higher at -3°C than at 3°C across all four corresponding mean comparisons; on Day 14, interleukin-1β and cluster of differentiation 34 expression were higher at -3°C across all four corresponding mean comparisons. Other molecular-marker comparisons showed less consistent directional patterns. Controlled superficial cooling therefore did not demonstrate enhanced wound closure, but selected genes showed consistent descriptive temperature-associated patterns. These exploratory findings suggest that controlled cold stress may influence the molecular wound environment without producing measurable improvement in macroscopic wound closure.

PMID 43040860
阅读全文 →
PubMedNature2026-11-17

Daily briefing: Are one-person firms the future of biotech?

Smith Jacob J

PMID 43040013
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多didanosine